Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors

Figures

• 

  FIGURE 1. Temporal trends in the proportions of cardiovascular (CV) death (PCV), cancer death (PCA), and other causes in all-cause deaths in patients with cancer. CVD, cardiovascular disease; RESPIR, respiratory; BREAST, breast; COLRECT, colon and rectum; URINARY, urinary; LYMYLEUK, lymphoma of all sites and leukemia; FEMGEN, female genital; MALEGEN, male genital; DIGOTHR, other digestive; OTHER, all other sites.

• 

  FIGURE 2. Competing mortality risk curves for patients with cancer who survived for more than 20 years by cancer sites. CVD, cardiovascular disease; RESPIR, respiratory; BREAST, breast; COLRECT, colon and rectum; URINARY, urinary; LYMYLEUK, lymphoma of all sites and leukemia; FEMGEN, female genital; MALEGEN, male genital; DIGOTHR, other digestive; OTHER, all other sites.

• 

  FIGURE 3. Cardiovascular mortality risk and anticancer treatments for patients with cancer who survived for more than 20 years by cancer sites. *A p-value of < 0.05. Marital status at diagnosis, race, calendar years at diagnosis according to 1970s, 1980s, 1990s, 2000s, 2010s, nine original registries, sex, SEER historic stage, surgery, radiotherapy and chemotherapy were adjusted in the multivariate competing risk regression models. HR (95%CI), Hazard ratio (95% confidence intervals); RESPIR, respiratory; BREAST, breast; COLRECT, colon and rectum; URINARY, urinary; LYMYLEUK, lymphoma of all sites and leukemia; FEMGEN, female genital; MALEGEN, male genital; DIGOTHR, other digestive; OTHER, all other sites.